Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05177939
Other study ID # NPB-01-19/C-01
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 3, 2022
Est. completion date October 31, 2024

Study information

Verified date January 2022
Source Nihon Pharmaceutical Co., Ltd
Contact Mamoru Ota
Phone 03-5148-7574
Email kaihatsu@nihon-pharm.co.jp
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date October 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria - < At 1st registration > Patients meeting the possible diagnostic criteria for autoimmune encephalitis - < At 1st registration > Patients with a CASE score of 5 to 22 during the screening period - < At 1st registration > Patients with autoimmune encephalitis in progress (active and requiring therapeutic intervention) - < At 1st registration > IVIG therapy and steroid pulse therapy are considered necessary by the investigator. - < At 1st registration > Patients aged 15 years or older at the time of informed consent - < At 2nd registration > Patients who meet any of the following (1) to (6): 1. Definite diagnostic criteria for autoimmune limbic encephalitis 2. MRI evidence of demyelination (probable autoimmune encephalitis) 3. Probabilistic diagnostic criteria for anti-NMDAR encephalitis 4. Probabilistic diagnostic criteria for Bickerstaff brainstem encephalitis 5. Probabilistic diagnostic criteria for Hashimoto's encephalopathy 6. Diagnostic Criteria for Autoimmune Encephalitis with Negative but Probable Autoantibodies - < At 2nd registration > CASE score of 5 to 22 on Day 8 of the previous treatment period - < At 2nd registration > Patients who have had an inadequate response to steroid pulse therapy Exclusion Criteria: - < At 1st registration > Patients with strongly suspected infectious encephalitis - < At 1st registration > Patients who received immunoglobulin preparations within 8 weeks prior to informed consent - < At 1st registration > Patients who received plasma exchange within 4 weeks prior to informed consent - < At 1st registration > Patients who received immunosuppressants (Rituximab, cyclophosphamide, etc.) within 4 weeks prior to informed consent - < At 1st registration > Patients who have had tumor resection associated with autoimmune encephalitis within 4 weeks prior to informed consent - < At 1st registration > Patients with a history of shock or hypersensitivity to the ingredients of NPB-01 - < At 1st registration > Patients with known IgA deficiency - < At 1st registration > Patients with renal disorder - < At 1st registration > Patients with a current or previous history of cerebral or cardiovascular disorders (Asymptomatic cerebral infarction and myocardial infarction that occurred more than 5 years ago are not applicable.) - < At 1st registration > Patients at high risk of thromboembolism - < At 1st registration > Patients with haemolytic/blood loss anaemia - < At 1st registration > Immunosuppressed/immunocompromised patients - < At 1st registration > Patients with decreased cardiac function - < At 1st registration > Pregnant, expected (desired or planned) pregnant, or breastfeeding patients - < At 1st registration > Use of prohibited medications or treatment in this study - < At 1st registration > Patients who received investigational product in this study (re-enrollment prohibited) - < At 1st registration > Patients who have received treatment with investigational product other than this study within 4 months prior to informed consent - < At 1st registration > Patients with a history of hypersensitivity to methylprednisolone sodium succinate - < At 1st registration > Patients who have a tumor associated with autoimmune encephalitis and are considered to require resection during the study period. - < At 1st registration > Patients receiving intravenous general anesthetics or sedative hypnotics - < At 1st registration > Patients in coma - < At 1st registration > Ventilated patients - < At 1st registration > Patients who cannot undergo protocol-specified tests/assessments - < At 1st registration > Other patients considered ineligible for the study by the investigator - < At 2nd registration > Positive herpes simplex virus DNA qualitative test in the screening period. - < At 2nd registration > Serum creatinine = 2 times the upper limit of normal during the screening period. - < At 2nd registration > Total protein = 9 g/dL during the screening period. - < At 2nd registration > Patients with hematocrit = 55% during the screening period - < At 2nd registration > Patients who meet any of the exclusion criteria at the time of first registration

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
NPB-01
NPB-01 will be administered for the treatment of autoimmune encephalitis
NPB-01-ME
NPB-01-ME will be administered for the treatment of autoimmune encephalitis

Locations

Country Name City State
Japan Trial site 1 Ube Yamaguchi

Sponsors (1)

Lead Sponsor Collaborator
Nihon Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of responders in CASE (Clinical Assessment Scale in Autoimmune Encephalitis) A responder is defined as a patient whose CASE score at Week 4 of the post-treatment follow-up period after treatment with investigational product improved by 40% or more compared to the pre-treatment period. 4 weeks
Secondary CASE The change in CASE score at each time point after the start of treatment with investigational product compared with that on Day 8 of the pretreatment period will be compared between the arms. Changes in CASE scores divided into three segments (0 -4: excellent, 5 -9: moderate, 10 -27: poor) will also be compared.
In addition, the period until CASE score becomes 4 points or less after the start of treatment with investigational product will be checked.
1, 2, 3, 4, 6, 8, 12 weeks
Secondary mRS Changes in mRS at each time point after the start of investigational product treatment compared with Day 8 of the pretreatment period will be compared between the arms. 1, 2, 3, 4, 6, 8, 12 weeks
Secondary GCS To compare the change in GCS at each time point after the start of investigational product with that on Day 8 of the pretreatment period between the arms. 1, 2, 3, 4, 6, 8, 12 weeks
Secondary MMSE-J The change in MMSE-J at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms. 4, 8, 12 weeks
Secondary FAB The change in FAB at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms. 4, 8, 12 weeks
Secondary Disappearance of abnormal EEG findings The proportion of subjects in whom abnormal findings in EEG disappeared at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms. 4, 12 weeks
Secondary Disappearance of abnormal head MRI findings The proportion of subjects in whom abnormal findings in head MRI disappeared at each time point after the start of investigational product as compared with Day 8 of the pretreatment period will be compared between the arms. 4, 12 weeks
Secondary Cerebrospinal fluid test The proportion of subjects in whom the cell count returned to within the reference range (= 5/µl) and the proportion of subjects in whom the protein count returned to within the reference range (15.0 ~ 45.0 mg/dL) at each time point after the start of investigational product treatment as compared with Day 8 of the pretreatment period will be checked. 4, 12 weeks
Secondary Duration of hospitalization Duration of hospitalization after the start of treatment with investigational product to be compared between the arms. 12 weeks
Secondary mRS proportion The proportions of subjects with an mRS score of = 2, subjects with an improvement of = 1 point, and subjects with an improvement of = 2 points will also be compared.
Also, the time to mRS improvement after the start of treatment with investigational product (= 2 points, = 1 point improvement, = 2 points improvement) .
1, 2, 3, 4, 6, 8, 12 weeks
Secondary GCS proportion Changes in GCS when divided into three segments (15-13: Mild, 12-9: Moderate, 8-3: Severe) will also be compared.
In addition, the period until the GCS score reaches 13 or higher after the start of treatment with investigational product will be checked.
1, 2, 3, 4, 6, 8, 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT05645185 - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
Completed NCT04708626 - Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting NCT04106596 - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Not yet recruiting NCT05711563 - Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Completed NCT04175522 - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: Phase 2
Recruiting NCT03194815 - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Phase 2
Recruiting NCT06079294 - Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism N/A
Not yet recruiting NCT03957616 - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed NCT02905136 - Mechanisms of Auto-immune Encephalitis
Recruiting NCT05280600 - Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Recruiting NCT06173076 - A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Recruiting NCT03993262 - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis Phase 2
Recruiting NCT06033846 - Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis Phase 2
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Active, not recruiting NCT06432803 - Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
Recruiting NCT06019975 - FDG-PET in the Diagnosis of Autoimmune Encephalitis
Completed NCT05783947 - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Not yet recruiting NCT06456736 - Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
Completed NCT05825690 - BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis